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ABSTRACT 
Objective: Cervical cancer is the third disease that causes death in the world. The main cause of cervical cancer is Human papillomavirus (HPV). HPV 
have E6 and E7 oncogenes that, responsible for cancer incidence. One of molecular biology techniques for HPV identification is PCR. The aimed of 
this study is to applicate the multiplex PCR primer design for HPV type 45 and 52 identification. 
Methods: DNA was isolated from 31 cervical cancer biopsy and cervical smear samples. DNA was amplicated with MY09/MY11 primer. Line probe 
array used to genotype of HPV. Application of primer design use MPCR methods with conditions was hot start 95 °C (3 min), denaturation 95 °C (15 
s), annealing 58 °C (30 s), extension 72 °C (15 s) and final extension 72 °C (1 min). The amplified products were analyzed on a 1.5% agarose gel, 
stained with Gel Red and visualized in-gel documentation system. 
Results: Result of HPV identification of HPV shown 19 of the 31 samples in this study was positive HPV. HPV genotyping was obtained the HPV type 
of the samples were HPV type 16, 18, 45 and 52. Application of design primer gives positive result. The band on S1, S2, S3 and S4 lane indicated the 
presence of gen E6 of HPV type 45 in J.1, J.3 and J.14 sample code and HPV type 52 in J.22 sample code. 
Conclusion: MPCR primer design for E6 gene of HPV type 45 and 52 was applicated for identification of HPV type 45 and 52 in cervical cancer 
patients. 
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Cervical cancer is a malignant tumor that begins with the growth of 
abnormal cells in the cervical epithelium [1]. Cervical cancer is the 
third disease that causes death in the world with estimated 35,673 
of deaths and 83,195 new cases of cervical cancer, while in 
Indonesia, cervical cancer is the second disease cause of death in 
women, especially in 15-44 y women [2]. 
World Health Organization (2007) stated that the main cause of 
cervical cancer is Human papillomavirus (HPV) [3]. HPV can be 
transmitted through sexual intercourse. HPV was classified into 
high-risk HPV and low-risk HPV. High risk HPV (HPV type 16, 18, 31, 
33, 34, 35, 39, 45, 51, 52, 56, 8, 59, 66, 68, and 82) is the group can 
cause cancer, especially cervical cancer [4]. ICO HPV Information 
Centre (2014) states that the prevalence rate of cervical cancer in 
Indonesia is 7.4% for HPV types 45 and 8.3% for HPV type 52 [2]. 
Based on Aldi (2015) research the prevalence of HPV type 45 for 
the region Sumatra and Riau were 60.47 
HPV have E6 and E7 oncogenes responsible for cancer incidence. E6 
and E7 genes play a role in encoding an oncoprotein that will help 
replication of the virus, immortality, and cell transformation. 
Identification of HPV types required specific gene in the virus that 
causes cervical cancer, so the E6 and E7 genes is used to determine 
the HPV type [6]. HPV identification uses molecular biology 
techniques, like polymerase chain reaction (PCR). Identification of 
HPV using multiplex PCR method. The procedure of identification 
with multiplex PCR use more than one pair of primer, so we can 
identification many types of HPV only on a PCR process. This 
technique is more efficient than conventional PCR 
% [5]. 
The most important part in PCR is a primer. Primer is a series of 
proteins that will amplified the target of DNA. In this study, 
identification of genes E6 HPV type 45 and 52 use multiplex primer 
design [7]. The aimed of this study is to applicate the multiplex PCR 
primer design for HPV type 45 and 52 identification in cervical 
cancer patients using multiplex PCR method. 
The samples used in this study is 24 cervical cancer biopsy and 7 
cervical smears derived from M. Djamil General Hospital, Padang 
and Arifin Achmad, Pekanbaru [5]. The tissue samples were isolated 
using DNA Extraction Kit gSYNCTM and cervical smear samples 
were isolated using Genomic DNA Mini LinkTM Pure Kit (Invitrogen 
TM). Isolation of DNA was done according to the protocol of the kit 
being used [5]. 
HPV identification used MY09/MY11 primers. The PCR conditions 
were hot start 94 °C (5 min), denaturation 94 °C (45 s), annealing 
55 °C (45 s), extension 72 °C (45 s) and final extension 72 °C (5 min). 
The amplified products were analyzed on a 1.5% agarose gel, 
stained with gel red and visualized in-gel documentation system. 
Line probe array used to genotyping of HPV. DNA was amplicated 
with MY09/MY11 primer by giving biotin as a label on one of the 
primer. Genotype-specific probe stopped on the membrane. 
Amplicon and the genotype-specific probe were mixed. 
Hybridization washed, and the expected band would stay. 
Streptavidin added in an alkaline environment (alkali posphatase), 
substrates was added and the band on the strip was detected [8]. 
The primers used in this study were HPV type 45 E6 gene 
primer (forward primer 5’-TGC GGT GCC AGA AAC CAT TGA-3’ 
and reverse primer 3’-TTT CTT GCC GTG CCT GGT CA-5’) with 
product length 129 bp and HPV type 52 E6 gene primer (forward 
primer5’-CAC GAA TTG TGT GAG GTG CTG-3’ and reverse primer3
The result of HPV identification of HPV shown 19 of the 31 samples in 
this study was positive HPV (Table. 1). HPV genotyping was obtained 
the HPV type of the samples were HPV type 16, 18, 45 and 52 (table 1). 
’-
GGT CAC AGG TCG GGG TCT-5’) with product length 402 bp [7].  
Primer MY09/MY11 is a general primer that has been used in many 
studies. MY09/MY11 primer commonly used in environmental 
epidemiology north and south America and Asia. Based on Weimin, 
et al., (1997) research, MY primer detects more than GP primer with 
ratio 90%: 46.7 [9]. In this study, positive results indicate with a 
band on 450 bp [10]. All of the positive HPV samples were cervical 
cancer biopsy samples, and no cervical smear had HPV DNA in this 
study. The prevalence of HPV in this study was 61.29% (n=19) of 23 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 3, 2016 
Aldi et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 382-384 
 
383 
samples, compared with previous research using GP primer, the 
prevalence of HPV was 60,47% (n=26) of 43 samples [5]. From this 
data known that no significant result between GP and MY primer in 
the identification of HPV DNA. 
High risk HPV, in general, is more often present in patients with 
cervical cancer are HPV 16, HPV 18, HPV 45, HPV 52, HPV 31, HPV 
33, and HPV 35 and so on. The results linear array probe found type 
of positive DNA samples was high-risk HPV such as HPV 16, HPV 18, 
HPV type 45 and HPV type 52. The result of this study shown that 
the designed primer gives positive result (Fig.1).  
The thin band on S1, S2, and S3 line still indicated the presence of 
gen E6 of HPV type 45 in sample 1,3 and 14. E6 gene has a role in 
encodes an oncoprotein that will help replication of the virus, 
immortality and cell transformation which is the host of HPV DNA 
[6]. Based on this results in proof that the multiplex primer design 
can be used to identification of HPV type 45 and 52. 
 
Table 1: Shows identification of Human Papillomavirus using line probe array 
S. No. Samples code Result of HPV identification Result of HPV 
1 J.1 + HPV 45 
2 J.2 + HPV 18 
3 J.3 + HPV 45 
4  J.4 - - 
5 J.5 + HPV 16 
6 J.6 - - 
7 J.7 - - 
8 J.8 + HPV 18 
9 J.9 + HPV 18 
10 J.10 + HPV 18 
11 J.11 - - 
12 J.12 + HPV 16 
13 J.13 + HPV 16 
14 J.14 + HPV 45 
15 J.15 + HPV 16 
16 J.16 + HPV 18 
17 J.17 - - 
18 J.18 + HPV 18 
19 J.19 + HPV 18 
20 J.20 + HPV 18 
21 J.21 + HPV 18 
22 J.22 + HPV 52 
23 J.23 + HPV 16 
24 J.24 + HPV 16 
25 A.1 - - 
26 A.2 - - 
27 A.3 - - 
28 A.4 - - 
29 A.5 - - 
30 A.6 - - 
31 A.7 - - 
Sample code J.1-J.24 is code for cervical cancer biopsy samples, samples code A.1-A.7 is code for cervical smear samples. 
 
 
Fig. 1: Multiplex PCR Tests HPV type 45 and HPV type 52 
 
Fig. 1 shown that HPV type 45 appear a band at 402 bp while HPV type 
52 is appear a band at 129 bp. Molecular diagnosis of HPV infection is 
very important for cervical cancer screening. Commonly methods, 
such as hybrid capture (HC2), in situ hybridization and PCR, is very 
good in terms of sensitive and specificity. Nowaday, PCR most widely 
used in a wide range of molecular diagnostic because of its ability to 
detect small fragments of deoxyribonucleic acid (DNA) [11, 12]. 
In this study, HPV type 45 and 52 was identification used multiplex 
PCR method. This method can detect some types of HPV in one tube 
at one time. Multiplex PCR is very advantageous because minimizing 
the use of materials, time and costs. The most important materials in 
PCR are a primer and DNA templates, but multiplex PCR have a 
different composition with conventional PCR. Multiplex PCR 
requires more than a pair of primers, template DNA, the molecule of 
water and dimethyl sulfoxide (DMSO). DMSO on multiplex PCR used 
to inhibit the activity of taq polymerase thus reducing amplification 
product. DMSO can increase amplification and enzyme interaction.  
MPCR primer design for E6 gene of HPV type 45 and 52 was 
applicated for identification of HPV type 45 and 52 in cervical cancer 
patients. There are three positive samples HPV type 45 (J.1, J.3, J.14) 
and 1 positive samples HPV type 52 (J.22) from 31 samples from the 
cervical tissue and smears. MPCR primer testing showed positive 
results with the band that came out in the size of 129 bp and 402 bp. 
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